Laurion Capital Management’s Editas Medicine EDIT Stock Holding History

Laurion Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-17,648	Closed	-$82.4K	–	395
2024 Q2	$82.4K	Buy	+17,648	New	+$99.6K	﹤0.01%	514
2023 Q2	–	Sell	-140,000	Closed	-$1.01M	–	625
2023 Q1	$1.01M	Hold	140,000	–	–	0.01%	305
2022 Q4	$1.24M	Sell	140,000 -659	-0.5%	-$7.23K	0.01%	319
2022 Q3	$1.72M	Buy	+140,659	New	+$2.19M	0.01%	338
2020 Q3	–	Sell	-36,200	Closed	-$1.07M	–	914
2020 Q2	$1.07M	Buy	+36,200	New	+$946K	0.01%	414

Other funds holding EDIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Laurion Capital Management's EDIT Position: Q3 2024 in Review

Laurion Capital Management sold out of Editas Medicine (EDIT) in Q3 2024, closing a stake of 17,648 shares — an estimated $82.4K sold.

Laurion Capital Management first reported a position in EDIT in Q2 2020 and held it in 5 quarters. The position peaked at $1.72M in Q3 2022. 229 funds tracked by Wall St. Rank hold EDIT as of Q3 2024.

Laurion Capital Management reported no remaining Editas Medicine position as of Q3 2024 after selling out during the quarter.
Laurion Capital Management sold 17,648 Editas Medicine shares in Q3 2024, an estimated $82.4K.
Laurion Capital Management first reported a position in Editas Medicine in Q2 2020 and held it in 5 quarters.
Laurion Capital Management's Editas Medicine position peaked at $1.72M in Q3 2022.
229 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2024.

Based on Laurion Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.